Alessia Gozzini

Dr. Alessia Gozzini

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FGFrancesca Girolami
Francesca Girolami
AGAlessia Gozzini
Alessia Gozzini
Eszter Dalma PalinkasEszter Dalma Palinkas
Eszter Dalma Palinkas
ABAdelaide Ballerini
Adelaide Ballerini
ATAlessia Tomberli
Alessia Tomberli
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto
Genetic counselling and genetic testing in hypertrophic cardiomyopathy (HCM) represent an integral part of the diagnostic algorithm to confirm the diagnosis, distinguish it from phenocopies, and suggest tailored therapeutic intervention strategies. Additionally, they enable cascade genetic testing in the family. With the implementation of Next Generation Sequencing technologies (NGS), the interpretation of genetic data has become more complex. In this regard, cardiologists play a central role, aiding geneticists to correctly evaluate the pathogenicity of the identified genetic alterations. In the ideal setting, geneticists and cardiologists must work side by side to diagnose HCM as well as convey the correct information to patients in response to their many questions and concerns. After a brief overview of the role of genetics in the diagnosis of HCM, we present and discuss the frequently asked questions by HCM patients throughout our 20-year genetic counselling experience. Appropriate communication between the team and the families is key to the goal of delivering the full potential of genetic testing to our patients.

31 May 2025 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
Marco FabianiMarco Fabiani
Marco Fabiani
CMCaterina Micolonghi
Caterina Micolonghi
SCSilvia Caroselli
Silvia Caroselli
CSCamilla Savio
Camilla Savio
SPSimona Petrucci
Simona Petrucci
MPMaria Piane
Maria Piane

14 December 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MZmattia zampieri
mattia zampieri
CFChiara Di Filippo
Chiara Di Filippo
chiara zocchichiara zocchi
chiara zocchi
VFVera Fico
Vera Fico
CGCristina Golinelli
Cristina Golinelli
SFSilvia Favilli
Silvia Favilli
Restrictive cardiomyopathy (RCM) is characterized by restrictive ventricular pathophysiology determined by increased myocardial stiffness. While suspicion of RCM is initially raised by clinical evaluation and supported by electrocardiographic and echocardiographic findings, invasive hemodynamic evaluation is often required for diagnosis and management of patients during follow-up. RCM is commonly associated with a poor prognosis and a high incidence of heart failure, and PH is reported in paediatric patients with RCM. Currently, only a few therapies are available for specific RCM aetiologies. Early referral to centres for advanced heart failure treatment is often necessary. The aim of this review is to address questions frequently asked when facing paediatric patients with RCM, including issues related to aetiologies, clinical presentation, diagnostic process and prognosis.

1 April 2024 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
EBElena Bennati
Elena Bennati
GCGuglielmo Capponi
Guglielmo Capponi
SFSilvia Favilli
Silvia Favilli
FGFrancesca Girolami
Francesca Girolami
AGAlessia Gozzini
Alessia Gozzini
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto

10 June 2022 in Cardiogenetics
Verified
Journal Article
Open access
PDF file
FGFrancesca Girolami
Francesca Girolami
SPSilvia Passantino
Silvia Passantino
ABAdelaide Ballerini
Adelaide Ballerini
AGAlessia Gozzini
Alessia Gozzini
GPGiulio Porcedda
Giulio Porcedda
SFSilvia Favilli
Silvia Favilli
Restrictive cardiomyopathy (RCM) is a rare disease of the myocardium caused by mutations in several genes including TNNT2, DES, TNNI3, MYPN and FLNC. Individuals affected by RCM often develop heart failure at a young age, requiring early heart transplantation. A 7-year-old patient was referred for genetic testing following a diagnosis of restrictive cardiomyopathy. Clinical exome sequencing analysis identified a likely pathogenic mutation in the FLNC gene [(NM_001458.5 c.6527_6547dup p.(Arg2176_2182dup)]. Its clinical relevance was augmented by the fact that this variant was absent in the parents and was thus interpreted as de novo. Genetic testing is a powerful tool to clarify the diagnosis, guide intervention strategies and enable cascade testing in patients with pediatric-onset RCM.

12 September 2025 in Cardiogenetics
Verified
Journal Article
Open access
PDF file
SGSara Giovani
Sara Giovani
ABAdelaide Ballerini
Adelaide Ballerini
AGAlessia Gozzini
Alessia Gozzini
MLMichele Di Lorenzo
Michele Di Lorenzo
DMDavide Mei
Davide Mei
FGFrancesca Girolami
Francesca Girolami
This study investigates the genetic background of pediatric-onset cardiac channelopathies, a rare group of genetic disorders causing arrhythmias and sometimes sudden death, whose genetic background remains partially unknown. The research analyzed 59 pediatric patients (<18 years of age) diagnosed with different channelopathies (LQTS, BrS, CPVT, SQTS, and conduction disorders), along with 40 of their family members, using Next-Generation Sequencing (NGS) after genetic counseling. A causative genetic variant was found in 47% of cases, mainly in the KCNQ1 (42%), RYR2 (16%), CACNA1C (10%), and SCN5A (10%) genes. Notably, a de novo large deletion in KCNH2 was detected in an LQTS patient, and a pathogenic CALM1 variant was identified in a child. A compound heterozygous KCNQ1 was consistent with Jervell and Lange-Nielsen syndrome. In light of these data, genetic testing is crucial for diagnosis, prognosis, and treatment planning; cascade screening allowed early risk identification and preventive interventions for family members. Expanding NGS technologies and research on new candidate genes may enhance personalized therapies in the future.